Healthcare
No matter how we manage our health, efficacy, risks and costing are top concernsRheumatoid arthritis medications with increasing dose of certolizumab pegol no help reduces the disease activity
Increasing the dosage of centrolizumab pegol in rheumatoid arthritis (RA) patients who had no response with this agent is no help to improve the disease activity, even with selected candidates.
This conclusion appeared after the researchers conducted open-label extension trial among 240 RA patients.
Overall, the investigators said that “dose escalation from 200 mg to 400 mg every other week appears to be of negligible benefit, even for selected individuals”, after 52 weeks of therapy.
In fact, according to the investigators, switch to other therapy more useful than increasing the dose of certolizumab pegol.
The report archived in Arthritis & Rheumatism in April 11, 2011.
The investigators concluded that for the patients with an inadequate response to certolizumab pegol, “changing therapies is preferred to dose escalation”.
Related Posts:
Subscribe for latest health news via email
